vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v13i4.1092vsp-175Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEПРОБИОТИКИ И БАКТЕРИАЛЬНЫЕ ИММУНОМОДУЛЯТОРЫ ДЛЯ ПРОФИЛАКТИКИ РЕСПИРАТОРНЫХ ИНФЕКЦИЙPROBIOTICS AND BACTERIAL IMMUNOMODULATORS FOR PREVENTION OF RESPIRATORY INFECTIONSХорошиловаН. В.KhoroshilovaN. V.

Khoroshilova Nataliya Viktorovna, allergologist and immunologist, associated professor of the Department of Clinical Immunology and Allergology

immuno1@rambler.ruИнститут повышения квалификации ФМБА, МоскваРоссияInstitute of Advanced Training FMBA, MoscowRussian Federation201402082014134Вопросы современной педиатрии9395Copyright © Хорошилова Н.В., 20142014Хорошилова Н.В.Khoroshilova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/175

Частые респираторные инфекции являются фактором риска развития хронических воспалительных заболеваний респираторного тракта и бронхиальной астмы. Вместе с тем возникающие в системе иммунитета на уровне слизистых оболочек нарушения могут привести к воспалению слизистой оболочки пищеварительного и урогенитального тракта. Традиционно профилактика острых респираторных инфекций включает санацию очагов инфекций, а также ликвидацию дисбиоза и иммунного дисбаланса с применением пробиотиков и бактериальных иммуномодуляторов. При этом пробиотические средства необходимы не только для восстановления нормальной микрофлоры на слизистых оболочках (в первую очередь, в желудочно-кишечном тракте), но и для оптимизации иммунокорригирующей терапии, особенно в тех случаях, когда используются иммуномодуляторы для перорального применения.

острые респираторные инфекциипробиотикибактериальные иммуномодуляторыпрофилактикаacute respiratory infectionsprobioticsbacterial immunomodulatorspreventionООО «Такеда Фармасьютикалс»“Takeda Pharmaceuticals”, Ltd.ReferencesFendrick A. M., Monto A. S., Nightengale B., Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch. Interrn. Med. 2003; 163: 487–494.Fendrick A. M., Monto A. S., Nightengale B., Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch. Interrn. Med. 2003; 163: 487–494.Markova T. P. Chasto i dlitel’no boleyushchie deti: vzglyad immunologa [Long-term and Sickly Children: Immunologist’s Opinion]. Moscow, 2014. 192 p.Markova T. P. Chasto i dlitel’no boleyushchie deti: vzglyad immunologa [Long-term and Sickly Children: Immunologist’s Opinion]. Moscow, 2014. 192 p.Mel’nik O. V. Tsitomegalovirusnaya i Epshtein-Barr-virusnaya infektsiya u chasto boleyushchikh detei s porazheniem dykhatel’nykh putei. Avtoref. dis. … kand. med. nauk [Cytomegalovirus and EpsteinBarr Virus Infection in Sickly Children with Lesions of the Respiratory Tract. Author’s abstract]. St. Peteresburg, 2011. 21 p.Mel’nik O. V. Tsitomegalovirusnaya i Epshtein-Barr-virusnaya infektsiya u chasto boleyushchikh detei s porazheniem dykhatel’nykh putei. Avtoref. dis. … kand. med. nauk [Cytomegalovirus and EpsteinBarr Virus Infection in Sickly Children with Lesions of the Respiratory Tract. Author’s abstract]. St. Peteresburg, 2011. 21 p.Sultanova O. D. Sostoyanie mikroekologii kishechnika u chasto i dlitel’no boleyushchikh detei. Avtoref. dis. … kand. med. nauk [Condition of Microecology of Intestine in Frequently and Chronically Ill Children. Author’s abstract]. Moscow, 2005. 22 p.Sultanova O. D. Sostoyanie mikroekologii kishechnika u chasto i dlitel’no boleyushchikh detei. Avtoref. dis. … kand. med. nauk [Condition of Microecology of Intestine in Frequently and Chronically Ill Children. Author’s abstract]. Moscow, 2005. 22 p.Shishkina T. A. Sostoyanie mikrobiotsenoza zheludochnokishechnogo trakta i ego korrektsiya u chasto i dlitel’no boleyushchikh detei v usloviyakh krupnogo promyshlennogo goroda. Avtoref. dis. … kand. med. nauk [Microbiocenosis Condition of the Gastrointestinal Tract and its Correction in Frequently and Chronically Ill Children in a Large Industrial City. Author’s abstract]. Voronezh, 2005. 23 p.Shishkina T. A. Sostoyanie mikrobiotsenoza zheludochnokishechnogo trakta i ego korrektsiya u chasto i dlitel’no boleyushchikh detei v usloviyakh krupnogo promyshlennogo goroda. Avtoref. dis. … kand. med. nauk [Microbiocenosis Condition of the Gastrointestinal Tract and its Correction in Frequently and Chronically Ill Children in a Large Industrial City. Author’s abstract]. Voronezh, 2005. 23 p.Khoroshilova N. V. Kliniko-immunologicheskaya otsenka effektivnosti ribomunila i nizkointensivnoi lazernoi terapii u bol’nykh khronicheskim bronkhitom. Avtoref. dis. … kand. med. nauk [Clinical and Immunological Evaluation of the Effectiveness of Ribomunil and Low-level Laser Therapy in Patients with Chronic Bronchitis. Author’s abstract]. Moscow, 1994. 21 p.Khoroshilova N. V. Kliniko-immunologicheskaya otsenka effektivnosti ribomunila i nizkointensivnoi lazernoi terapii u bol’nykh khronicheskim bronkhitom. Avtoref. dis. … kand. med. nauk [Clinical and Immunological Evaluation of the Effectiveness of Ribomunil and Low-level Laser Therapy in Patients with Chronic Bronchitis. Author’s abstract]. Moscow, 1994. 21 p.Khoroshilova N. V. Vopr. sovr. pediatrii — Current pediatrics. 2013; 12 (5): 86–90.Khoroshilova N. V. Vopr. sovr. pediatrii — Current pediatrics. 2013; 12 (5): 86–90.Lehtoranta L., Pitkaranta A., Korpela R. Probiotics in respiratory virus infections. Eur. J. Clin. Microbiol. Infect. Dis. Published online: 18 march 2014.Lehtoranta L., Pitkaranta A., Korpela R. Probiotics in respiratory virus infections. Eur. J. Clin. Microbiol. Infect. Dis. Published online: 18 march 2014.Lenoir-Wijnkoop I. Public health impact of probiotics in common respiratory tract infections. Beneficial Microbes. 2014; 5 (Suppl. 1):Lenoir-Wijnkoop I. Public health impact of probiotics in common respiratory tract infections. Beneficial Microbes. 2014; 5 (Suppl. 1):10. Davidson L. E., Fiorino A. M., Snydman D. R., Hibberd P. L. Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. Eur. J. Clin. Nutr. 2011; 65 (4): 501–507.10. Davidson L. E., Fiorino A. M., Snydman D. R., Hibberd P. L. Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. Eur. J. Clin. Nutr. 2011; 65 (4): 501–507.Akatsu H., Arakawa H., Yamamoto T., Kanematsu T., Matsukawa N., Ohara H. Lactobacilli in jelly enhances the effect of influenza vaccination. J. Am. Geriatr. Soc. 2013; 61 (10): 1828–1830.Akatsu H., Arakawa H., Yamamoto T., Kanematsu T., Matsukawa N., Ohara H. Lactobacilli in jelly enhances the effect of influenza vaccination. J. Am. Geriatr. Soc. 2013; 61 (10): 1828–1830.Olivares M., Diaz-Ropero H. P., Sierra S., Lara-Villostada F., Fonolia J., Navas M. et al. Oral intake of Lactobacillus fermentum CECT5716 enhances the effect of influenza vaccination. Nutrition. 2007; 23 (3): 254–260.Olivares M., Diaz-Ropero H. P., Sierra S., Lara-Villostada F., Fonolia J., Navas M. et al. Oral intake of Lactobacillus fermentum CECT5716 enhances the effect of influenza vaccination. Nutrition. 2007; 23 (3): 254–260.Rizzardini G., Eskesen D., Calder P. C., Capetti A., Jespersen L., Clerici M. Evaluation of the immune effects of two probiotic strains Bifidobacterium animalis, BB lactis, BB-12 and Lactobacillus paracasei ssp. paracasei, L. casei 431 in an influenza vaccination model: a randomized double-blind placebo controlled study. Brit. J. Nutr. 2012; 107 (6): 876–884.Rizzardini G., Eskesen D., Calder P. C., Capetti A., Jespersen L., Clerici M. Evaluation of the immune effects of two probiotic strains Bifidobacterium animalis, BB lactis, BB-12 and Lactobacillus paracasei ssp. paracasei, L. casei 431 in an influenza vaccination model: a randomized double-blind placebo controlled study. Brit. J. Nutr. 2012; 107 (6): 876–884.Bosch H. M., Mendez M., Perez M., Farran A., Fuentes M. C., Cuune J. Lactobacillus plantarum CEC P7315 and CEC P7316 stimulate.Bosch H. M., Mendez M., Perez M., Farran A., Fuentes M. C., Cuune J. Lactobacillus plantarum CEC P7315 and CEC P7316 stimulate.Boyle R. J., Robins-Browne R. M., Tang M. L. K. Probiotic use in clinical practice: what are the risks? Am. J. Clin. Nutr. 2006; 83: 1256–1264.Boyle R. J., Robins-Browne R. M., Tang M. L. K. Probiotic use in clinical practice: what are the risks? Am. J. Clin. Nutr. 2006; 83: 1256–1264.Kalima P., Masterton R. G., Roddie P. H., Thomas A. T. Lactobacil lus rhamnosus infection in a child following bone marrow transplantat. J. Infect. 1996; 32: 165–167.Kalima P., Masterton R. G., Roddie P. H., Thomas A. T. Lactobacil lus rhamnosus infection in a child following bone marrow transplantat. J. Infect. 1996; 32: 165–167.Land M. H., Rouster-Stevens K., Woods C. R., Cannon M. L., Cnota J., Shetty A. K. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005; 115: 178–181.Land M. H., Rouster-Stevens K., Woods C. R., Cannon M. L., Cnota J., Shetty A. K. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005; 115: 178–181.Smith P. D., MacDonald T., Blumberg R. S. Principles of mucosal immunology. London and New York: Garland Science. 2013. 512 p.Smith P. D., MacDonald T., Blumberg R. S. Principles of mucosal immunology. London and New York: Garland Science. 2013. 512 p.Liao J. Y., Zhang T. Influence of OM-85BV on hBD-1 and immunoglobulin in children with asthma and recurrent respiratory tract infection. Zhongguo Dang Dai Er Ke Za Zhi. 2014; 16 (5): 508–512.Liao J. Y., Zhang T. Influence of OM-85BV on hBD-1 and immunoglobulin in children with asthma and recurrent respiratory tract infection. Zhongguo Dang Dai Er Ke Za Zhi. 2014; 16 (5): 508–512.Schaad U. B. OM-85BV an immunostimulant in pediatric recurrent respiratory tract infection: a systemic review. World J. Pediatr. 2010; 6 (1): 5–12.Schaad U. B. OM-85BV an immunostimulant in pediatric recurrent respiratory tract infection: a systemic review. World J. Pediatr. 2010; 6 (1): 5–12.Steurer-Stay C., Ladler L., Straub D. A., Steurer J., Bachmann L. M. Oral purified bacterial extracts in acute respiratory tract infections in childhood. Eur. J. Pediatr. 2007; 166 (4): 365–376.Steurer-Stay C., Ladler L., Straub D. A., Steurer J., Bachmann L. M. Oral purified bacterial extracts in acute respiratory tract infections in childhood. Eur. J. Pediatr. 2007; 166 (4): 365–376.Sprenkle M. D., Newoehner D. E., MacDonald R., Rutks I., Wilt T. J. Clinical efficacy of OM-85BV in COPD and chronic bronchitis: a systematic review. COPD. 2005; 2 (1): 167–175.Sprenkle M. D., Newoehner D. E., MacDonald R., Rutks I., Wilt T. J. Clinical efficacy of OM-85BV in COPD and chronic bronchitis: a systematic review. COPD. 2005; 2 (1): 167–175.Esposito S., Marchisio P., Prada E., Daleno C., Porretti L., Carsett R. et al. Impact of mixed bacterial lysate (OM-85BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection. Vaccine. 2014; 32 (22): 2546–2552.Esposito S., Marchisio P., Prada E., Daleno C., Porretti L., Carsett R. et al. Impact of mixed bacterial lysate (OM-85BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection. Vaccine. 2014; 32 (22): 2546–2552.

The authors declare that there are no conflicts of interest present.